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PärIngemar Johansson1,2,3*, Jakob Stensballe1,4 and SisseRye Ostrowski1Abstract
One quarter of patients suffering from acute critical illness such as severe trauma, sepsis, myocardial infarction
(MI) or post cardiac arrest syndrome (PCAS) develop severe hemostatic aberrations and coagulopathy, which are
associated with excess mortality. Despite the different types of injurious “hit”, acutely critically ill patients share
several phenotypic features that may be driven by the shock. This response, mounted by the body to various
life-threatening conditions, is relatively homogenous and most likely evolutionarily adapted. We propose that
shock-induced sympatho-adrenal hyperactivation is a critical driver of endothelial cell and glycocalyx damage
(endotheliopathy) in acute critical illness, with the overall aim of ensuring organ perfusion through an injured
microvasculature. We have investigated more than 3000 patients suffering from different types of acute critical
illness (severe trauma, sepsis, MI and PCAS) and have found a potential unifying pathologic link between sympatho-
adrenal hyperactivation, endotheliopathy, and poor outcome. We entitled this proposed disease entity, shock-
induced endotheliopathy (SHINE). Here we review the literature and discuss the pathophysiology of SHINE.Background
Acute critical illness such as trauma, sepsis, myocardial in-
farction (MI) and post cardiac arrest syndrome (PCAS) af-
fects more than five million patients in the EU annually [1].
Approximately one quarter of acutely critically ill patients
develop severe hemostatic aberrations resulting in coagulop-
athy [2–4], which in patients suffering from severe injury is
entitled trauma-induced coagulopathy (TIC) [4, 5], and in
patients with sepsis and PCAS (and by some also in trauma
[6]) entitled disseminated intravascular coagulation (DIC)
[7–10]. Acutely critically ill patients with coagulopathy have
been reported to have three to four times higher mortality
rates than their counterparts without coagulopathy, translat-
ing into a mortality rate of approximately 50%, which has
remained virtually constant for decades [4, 7, 10].
In studies of trauma patients, increasing injury severity
score (ISS) is associated with progressive hypocoagulability* Correspondence: per.johansson@regionh.dk
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evolutionary perspective, as these patients are at high risk
of exsanguination and, therefore, would need an intact or
even improved hemostatic capacity of blood flow. We have
proposed that the coagulopathy observed in these patients
is a compensatory mechanism counterbalancing the shock-
induced pro-thrombotic vascular endothelium in the
microcirculation in order to secure sufficient organ per-
fusion in conditions with shock [12, 13]. Importantly,
systemic endothelial injury seems pivotal for the devel-
opment of organ failure and ensuing poor outcome [14,
15], pointing to a possible explanation of the associ-
ation between coagulopathy and poor outcome in acute
critical illness [8, 10, 16, 17].
The endothelium is one of the largest “organs” in the
body, with a total weight of approximately 1 kg and a
surface area of approximately 5000 m2 [18]. Endothelial
cells form the innermost lining of all blood and lymph-
atic vessels and extend to all reaches of the vertebrate
body. Far from being an inert layer of nucleated cello-
phane, the endothelium partakes in a wide array of
physiological functions, including control of vasomotor
tone, maintenance of blood fluidity, regulated transfer ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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innate and acquired immunity, angiogenesis and estab-
lishment of a unique dialogue between the underlying
tissue and the flowing blood [18]. It is also recognized
that the endothelium plays a critical role in a multitude
of diseases, such as arteriosclerosis, malignancy and
acute inflammatory diseases either as a primary deter-
minant of pathophysiology or as a victim of collateral
damage [19, 20].
Under normal conditions the endothelium is anticoa-
gulated by a number of natural anticoagulant systems in-
cluding the negatively charged luminal surface layer, the
glycocalyx, which is rich in heparonoids and interacts
with antithrombin [21]. Furthermore, tissue factor path-
way inhibitor (TFPI) and the protein C/thrombomodulin
system also contribute to endothelial anticoagulation
along with endothelial release of tissue-type plasminogen
activator (tPA) and urokinase-type plasminogen activator
(uPA) that dissolves forming clots [22]. Hence, we
propose that shedding, degradation and/or release of the
glycocalyx and the natural anticoagulant and pro-
fibrinolytic factors from the injured endothelium induces
the profound hypocoagulability observed in acute critic-
ally ill patients with shock [12].
In trauma patients, TIC is present already at the scene
of the accident in the most severely injured, shocked
patients [23] indicating a potential contribution of the
sympatho-adrenal system to this “early” coagulopathy.
Cannon described in 1915 how the hormone adrenaline,
released immediately upon severe stress, mobilizes an
emergency response denoted the “fight or flight” response,
and furthermore that the sympatho-adrenal activation “or-
chestrates changes in blood supply, sugar availability and
the blood’s clotting capacity in a marshalling of resources
keyed to the violent display of energy” [24]. We propose
that the shock-induced sympatho-adrenal hyperactivation
and ensuing excessive increase in circulating levels of
catecholamines, not only activates but also directly inflicts
systemic damage to the endothelium, including the micro-
circulation [25, 26]. Apart from the obvious increased risk
of microvascular occlusion secondary to pro-thrombotic
microcirculation in these patients, capillary leakage alsoFig. 1 Shock-induced endotheliopathy (SHINE). Schematic illustration of th
severity and increasing sympatho-adrenal activation (Original figure)significantly contributes to disease progression due to
hypovolemia, edema, tissue hypoxia and exacerbated
shock, resulting in a viscous circle with sustained
sympatho-adrenal hyperactivation and release of large
amounts of catecholamines, further compromising the
microvasculature [27] (Fig. 1).
Here we describe and discuss the pathophysiology
of shock-induced endotheliopathy (SHINE), a pro-
posed new disease entity with unifying pathological
change observed in acutely critically ill patients chal-
lenged by shock.
Shock-induced endotheliopathy (SHINE)
We propose that shock, and its effect on the sympatho-
adrenal system, the endothelium, including the glycoca-
lyx and the hemostatic cells in the circulating blood
results in phenotypic features that characterize the
clinical condition of patients suffering acute critical ill-
ness, despite the different types of injurious “hit” they
suffer [6, 9, 15, 27–30]. The catecholamine-induced
damage to the endothelium is responsible for endothelial
breakdown resulting in glycocalyx shedding, breakdown
of tight junctions with capillary leakage and a pro-
coagulant microvasculature that further reduces oxygen
delivery due to increased tissue pressure and micro-
vascular thrombosis creating a vicious circle that ultim-
ately results in organ failure. The early genetic responses
to severe trauma, burn injury and endotoxemia are simi-
lar [31], indicating that the response mounted by the
body to various acute critical conditions accompanied by
shock, is relatively homogenous and most likely evolu-
tionarily adapted [12].
Endotheliopathy of traumatic shock
We have investigated the degree of coagulopathy,
sympatho-adrenal activation (plasma catecholamines) and
endothelial injury (circulating biomarkers of endothelial
cell (soluble thrombomodulin (sTM)) and glycocalyx (syn-
decan-1) damage) in three independent cohorts of se-
verely injured patients (total number 579) [5, 16, 32–35].
Here we found strong and independent associations
between high injury severity, high plasma adrenalinee changes in the vascular compartment with increasing disease
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syndecan-1 and sTM levels. High plasma adrenaline
was a strong and independent predictor of increased
mortality [32] and hypocoagulability [36] and, import-
antly, despite comparable injury severity, trauma pa-
tients with the highest syndecan-1 levels (reflecting the
highest degree of glycocalyx damage) had several-fold
higher mortality [16, 33]. This emphasizes the pivotal
importance of the state of the endothelium for out-
come in these patients and also points towards a pos-
sible genetic predisposition of the endothelial response
to shock. Furthermore, we found a significantly differ-
ent sympatho-adrenal and endothelial response to the
injurious “hit” in older vs. younger trauma patients,
indicating that patient age also appears to significantly
influence the response that is mounted, including the
degree of endotheliopathy [37]. This is in accordance
with the well-described association between higher age
and progressive disruption and dysfunction of the
endothelium, with the most profound endothelial dis-
ruption observed in smokers and patients with dia-
betes, hypertension or atherosclerosis [20, 38]. In
addition to age, gender also significantly influences the en-
dogenous trauma shock response [39] and both age and
male gender are strong and independent predictors of
multiple organ failure, an outcome closely linked to
endotheliopathy, following severe trauma [40].
The critical importance of glycocalyx shedding in TIC
was further illustrated by our finding that the most severely
injured trauma patients displayed evidence of endogenous
heparinization, as evaluated by whole blood thrombelasto-
graphy (TEG) [35]. Endogenous heparinization is the result
of the shedding of the glycocalyx, including heparan
sulphate having the same functional effects as heparin
on the hemostatic system. Also, damage to the endo-
thelial cells induces release of thrombomodulin in its
soluble form, which retains its anticoagulant effects
also when circulating in the blood. Patients with evi-
dent endogenous heparinization displayed four-fold higher
plasma syndecan-1 levels, strongly indicating that release
of heparin-like constituents from the glycocalyx induced
the endogenous heparinization. Patients with endogenous
heparinization also had higher transfusion requirements,
higher sTM levels and lower protein C levels compared to
patients without endogenous heparinization. This empha-
sizes that the endotheliopathy included both extensive
endothelial cell and glycocalyx damage [35, 41–44]. It
should be noted, however, that these intriguing data are
only observations and as such are hypothesis-generating,
and currently there is no firm evidence available from
RCTs to clarify whether endotheliopathy merely reflects
greater disease severity, which in turn is known to relate
to more organ dysfunction, or a severity-independent as-
sociation with organ injury.Endotheliopathy of septic shock
Septic coagulopathy evidenced by DIC has for decades
been associated with poor outcome [7, 8] and the ac-
companying endothelial dysfunction and injury are both
hallmarks and drivers of the poor outcome [8, 29]. Based
on the hypothesis that coagulopathy is a surrogate
marker and a result of systemic endotheliopathy, we
conducted a study investigating patients (n = 321) with
varying degrees of infectious disease ranging from sys-
temic inflammatory response syndrome (SIRS) without
infection or with local infection, to sepsis, severe sepsis
or septic shock [45]. Here we found that plasma
syndecan-1 and sTM increased progressively and signifi-
cantly across groups with increasing infectious severity
and correlated significantly with organ failure as mea-
sured by the sequential organ failure assessment (SOFA)
score in all groups. Furthermore, plasma levels of cate-
cholamines, syndecan-1 and sTM were significantly
higher in non-survivors compared to survivors and high
levels of both catecholamines, syndecan-1 and sTM were
all independent predictors of excess mortality, linking
sympatho-adrenal hyperactivation and endothelial dam-
age to outcome in patients with sepsis.
Patients with septic shock per definition receive vaso-
pressor treatment, most often noradrenaline. Given this,
it could be speculated whether the high therapeutic nor-
adrenaline concentrations further promote endothelio-
pathy in these patients. We investigated this in a small
study of patients (n = 67) of whom 21% received nor-
adrenaline infusion at the time of blood sampling [46].
The study demonstrated that the levels of a broad range
of biomarkers reflecting endothelial damage, including
syndecan-1 and sTM, did not differ between patients
with or without noradrenaline infusion, indicating that
endotheliopathy in patients with septic shock was not
further aggravated by catecholamine infusion [46].
Similarly, there was a strong association between
endotheliopathy and organ failure in a large multicenter
study of 1103 critically ill patients predominantly suffer-
ing from sepsis [47], demonstrating that patients with
sepsis had higher plasma levels of syndecan-1 and sTM
(more excessive endothelial damage) than non-infected
patients. When stratifying the patients into quartiles
based on sTM levels at study enrollment, mortality
could be differentiated across all four quartiles during
the entire follow-up period, with the highest mortality in
the highest sTM quartiles, even after adjusting for other
prognostic variables. Importantly, high syndecan-1 and
sTM levels independently predicted liver and renal fail-
ure, respectively, and high sTM was further associated
with increased risk of development of multiple organ
failure. In sensitivity analysis, a composite endpoint of
“circulatory failure or death” was created to overcome
potential lead bias, as inotropic/vasopressor drugs are
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ing for confounders, both syndecan-1 and sTM study
enrollment independently predicted the risk of “circula-
tory failure or death”, further pointing towards the cen-
tral role of endotheliopathy for the pathophysiology
related to outcome in patients with septic shock [47].
Finally, in a smaller cohort of 184 patients with severe
sepsis or septic shock we found an independent
association between high circulating syndecan-1 levels
and coagulopathy evaluated by TEG, further linking
endotheliopathy and coagulopathy also in sepsis [45].
Though it has been evident for decades that endothelial
injury is a hallmark of sepsis [8, 27, 29], new data keep
emerging that further reveal the pathophysiology of
endothelial cell and glycocalyx damage in sepsis and its
association with disease severity, including the applic-
ability of biomarkers for outcome [48–51]. Similar to
traumatic endotheliopathy, the findings described here
are observational and, hence, no causality can be
inferred.
Endotheliopathy of cardiogenic shock and cardiac arrest
Cardiac arrest is the ultimate ischemia-reperfusion “hit”
to the body. PCAS represents the systemic response to
the global ischemia-reperfusion injury [15], which
involves profound endothelial injury and ensuing micro-
circulatory dysfunction and failure secondary to capillary
leakage, tissue/organ edema and hypoxia and increased
blood cell adhesion to the activated/injured endothe-
lium. The consequence of this global ischemia-reperfusion
injury to the endothelium is a sepsis-like inflammatory
response [9, 15, 30] that ultimately drives organ failure
similarly to that observed in sepsis.
In 2007, Rehm and colleagues provided the first evi-
dence in humans for shedding of the endothelial glyco-
calyx in conditions with ischemia-reperfusion [52]. In
three groups of surgical patients (patients undergoing
thoracic aortic surgery with deep hypothermic cardiac
arrest, patients undergoing cardiac surgery on cardiopul-
monary bypass and patients undergoing surgery for an
abdominal aortic aneurysm) it was found that global and
regional ischemia was followed by an increase in both
syndecan-1 and heparan sulfate, two constituents of the
endothelial glycocalyx [52], a finding confirmed by later
studies [53].
Patients resuscitated from cardiac arrest frequently
demonstrate profound hypocoagulability and hyperfibri-
nolysis of the flowing blood along with shedding of the
glycocalyx [54, 55]. In a post-hoc analysis of 163 patients
included at our center, Rigshospitalet, in The Targeted
Temperature Management at 33 degrees versus 36 de-
grees after Cardiac Arrest (TTM) trial [56], we found
that catecholamines correlated strongly with syndecan-1
and sTM plasma levels i.e. biomarkers reflectingendothelial glycocalyx and cell damage [57]. Overall
180-day mortality was 35% and both plasma adrenaline
and sTM levels were the strongest, and independent,
predictors of mortality [57]. This finding is in line with
our previous study of 678 patients with acute ST-
elevation myocardial infarction (STEMI), demonstrating
that admission levels of plasma adrenaline, syndecan-1
and sTM were highly correlated with the highest levels
of adrenaline and syndecan-1 in patients with cardio-
genic shock [38]. Furthermore, STEMI patients admitted
to ICU displayed the highest syndecan-1 plasma levels
and high levels of adrenaline, syndecan-1 and sTM were
strong predictors of poor outcome, including heart fail-
ure and mortality [38].
Together these findings indicate that sympatho-
adrenal hyperactivation and endothelial damage are
inter-correlated and strong predictors of mortality in
conditions with cardiogenic shock [38, 57], and further-
more that myocardial infarction alone appears also to
inflict significant systemic endothelial damage, possibly
driven in part by the parallel increase in circulating
catecholamines, albeit evidence from prospective ran-
domized trials are lacking [38]. The finding, however, is
in alignment with previous studies reporting high
circulating levels of glycocalyx components (syndecan-1,
heparan sulphate) in patients with cardiogenic shock,
with high levels being strong predictors of excess mor-
tality [58].
Discussion
In the observational data presented here from more than
3000 patients with different types of acute critical illness
including different types of shock, high circulating cat-
echolamine levels are independently associated with
endotheliopathy and are predictive of poor outcome
(both short-term and long-term mortality) and, further-
more, that this shock-induced endotheliopathy is statisti-
cally linked to the development of organ failure and
death. Given that shock and endothelial disruption and
damage coincide in patients with the most severe form
of acute critical illness, a mechanistic link is suggested
between sympatho-adrenal hyperactivation and the
endothelial phenotype, and that this shock-induced
endotheliopathy (SHINE), may be a unifying pathophysi-
ologic mechanism, linked to outcome, albeit this awaits
further confirmation [12, 28].
Recently, a link between sympatho-adrenal hyper-
activation and endothelial damage was suggested in an
animal model of trauma shock demonstrating that both
chemical sympathectomy and treatment with β-blockade
attenuate endothelial glycocalyx and endothelial cell
damage in rats with acute traumatic coagulopathy [59].
This may provide an explanation for the limited success
of many large RCTs conducted in acutely critically ill
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severe sepsis/septic shock alone, more than 30,000 pa-
tients have been enrolled in clinical trials to test
anti-coagulant, anti-inflammatory, anti-endotoxin and
immune-modulating agents [60, 61]. Yet, not a single
agent has convincingly proven to be consistently effi-
cacious and there are still no new drugs on the mar-
ket with the indication of sepsis, despite tremendous
effort worldwide. Similarly, in patients suffering from
out of hospital cardiac arrest (OHCA), two small
RCTs (77 and 136 patients, respectively) conducted
in 2002 reported improved survival in those receiv-
ing therapeutic hypothermia targeted at approxi-
mately 33 °C [62, 63]. However, in a large RCT
including 939 patients randomized to temperatures
of 33 °C or 36 °C, there was difference between
groups in mortality [56], and a recent meta-analysis
of RCTs reported no benefit of mild therapeutic
hypothermia on neurologic outcome or mortality in
patients who had OHCA [64].
In trauma, mortality has been reduced substantially
in the past 10–15 years as a result of the introduction
of damage control surgery and hemostatic resuscita-
tion [65–67]. A recent multicenter RCT in trauma
patients with severe hemorrhage demonstrated a sig-
nificant reduction in early mortality caused by exsan-
guination, with more aggressive administration of
plasma and platelets [68]. Similarly, a recent RCT was
prematurely halted due to a significantly increased
survival of patients who were resuscitated aggressively
based on whole blood TEG compared to conventional
coagulation assays [69]. Unfortunately, the excess
mortality in patients with TIC has remained un-
changed by these improvements, highlighting a thera-
peutic failure here as well.
Given the potential unifying pathologic condition of
SHINE across patients with different types of acute crit-
ical illness, it could be speculated whether interventions
targeting the endothelium and/or the sympatho-adrenal
system could be of value here. By 1978, β-blocker ther-
apy had already been reported to have beneficial effects
on MI [70] and in a later meta-analysis of RCTs investi-
gating the use of early intravenous beta-blockers in
patients with acute coronary syndrome there were signifi-
cant reductions in the risk of short-term cardiovascular
events, including reduction in all-cause mortality [71].
The beneficial effects of β-blocker therapy in these pa-
tients have historically been envisioned to be related to
reductions in the incidence of arrhythmia and improved
cardiac myocyte function. However, we speculate that
blockade of the effects of the catecholamine surge on
the endothelium, and hereby reduced systemic endothe-
liopathy, may also have contributed to the improved out-
come and this should be investigated further. In a recentsmall RCT of patients with septic shock and heart rate
above 95 beats per minute, 77 patients were randomized
to either short-acting β-blocker therapy with Esmolol to
maintain heart rate between 80 and 94 beats per minute
during their ICU stay or to placebo [72]. Patients
receiving β-blocker therapy had lower 28-day mortality
compared to the control group (49% vs. 81%, adjusted
hazard ratio of 0.39).
Taken together these results may indicate that sym-
pathoadrenal hyper-activation may be hazardous for
acute critically ill patients and according to our pro-
posed hypothesis, use of β-blocker therapy in these pre-
vious trials may have prevented or reduced the
catecholamine-induced endotheliopathy, which trans-
lated into improved survival in patients suffering from
cardiac disease including cardiac arrest, trauma and sep-
sis. Adequately powered RCTs are necessary to confirm
or reject this hypothesis.
Conclusion
Shock-induced endotheliopathy (SHINE) is observed in
acute critical illness and may reflect a potential unifying
pathophysiologic mechanism linked to poor outcome.
Sympatho-adrenal hyperactivation appears to be a piv-
otal driver of this condition.
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